SYNTHESIS: To a solution of 25 g 2,5-dimethoxy-4-methylbenzaldehyde (see the recipe for
In a cooled high-pressure reaction vessel there was placed a suspension of 30 g 2,5-dimethoxy-4-methylcinnamic acid in 150 mL liquid isobutene. This was treated dropwise with 0.6 mL concentrated H2SO4, then sealed and brought to room temperature. After 48 h shaking, the vessel was cooled again to -10 °C, opened, and poured into 200 mL of 10% Na2CO3. This was extracted with hexane, the pooled extracts washed with H2O, and the solvent removed to yield 17.0 g of tert-butyl 2,5-dimethoxy-4-methylcinnamate as an amber oil. Anal. (C16H22O4) C,H.
The cyclopropane ester was prepared by the reaction between 16 g tert-butyl 2,5-dimethoxy-4-methylcinnamate and dimethylsulfoxonium methylide, prepared as described in the Kaiser reference in the acknowledgements. Hydrolysis of this ester gave 53% trans-2-(2,5-dimethoxy-4-methylphenyl)cyclopropanecarboxylic acid which, after recrystallization from a MeOH/H2O mixture, had a mp of 136 °C. Anal. (C13H16O4) C,H.
A suspension of 4 g of trans-2-(2,5-dimethoxy-4-methylphenyl)cyclopropanecarboxylic acid in an equal volume of H2O, was treated with sufficient acetone to effect complete solution. This was cooled to 0 °C and there was added, first, 2.0 g triethylamine in 35 mL acetone, followed by the slow addition of 2.5 g ethyl chloroformate in 10 mL acetone. This was stirred for 0.5 h, and then there was added a solution of 1.7 g NaN3 in 6 mL H2O, dropwise. After 1 h stirring at 0 °C, the mixture was quenched by pouring into H2O at 0 °C. The separated oil was extracted with Et2O, and extracts dried with anhydrous MgSO4. Removal of the solvent under vacuum gave a residue of the azide, which was dissolved in 10 mL anhydrous toluene. This solution was heated on the steam bath until the nitrogen evolution was complete, and the removal of the solvent under vacuum gave a residue of crude isocyanate as an amber oil. This intermediate isocyanate was dissolved in 5.4 g benzyl alcohol and the reaction mixture was heated on the steam bath for 6 h. The excess benzyl alcohol was removed by distillation, yielding trans-2-(2,5-dimethoxy-4-methylphenyl)carbobenzoxyamidocyclopropane as a crystalline residue. This was recrystallized from an EtOAc/hexane mixture to give 6.13 g of a crystalline product with a mp of 107–108 °C. Anal. (C20H23NO4) C,H,N.
A solution of 1.5 g trans-2-(2,5-dimethoxy-4-methylphenyl)carbobenzoxyamidocyclopropane in 120 mL MeOH containing 200 mg 10% Pd/C was shaken under hydrogen gas at 35 psig for 45 min. The solution was filtered through celite, and a sufficient amount of a solution of 5% HCl in EtOH was added to the filtrate to make it acidic. Removal of all volatiles under vacuum gave a solid residue that was recrystallized from an EtOH/ether mixture to give 0.98 g of trans-2-(2,5-dimethoxy-4-methylphenyl)cyclopropylamine hydrochloride (DMCPA) as white crystals with a mp of 210–211 °C.
DOSAGE: 15–20 mg.
DURATION: 4–8 h.
QUALITATIVE COMMENTS: (with 10 mg) “The effects were quite real at an hour, but very hard to define. Nothing left at four hours, but my sleep was filled with bizarre and colorful dreams. Something was still working somewhere, at some level.”
(with 20 mg) “I found myself lightheaded, and the thinness seemed to be, rather remarkably, on the left side of my brain. The experience was flighty. I was reminded of the aura that has been described preceding a convulsion. I was decoupled from my experience and from my environment. Not all of the control is there, and I am uncomfortable. But in an hour, there is complete control again, and I can relax my conscious guard which allows an easy plus three. With this, there was easy fantasy, erotic, quite a bit of movement in the visual field, and mild anorexia. The residual hyperreflexive thinness is largely gone, and not at all worrisome. This stuff is complicated, with a little too much of the physical. The next day was without any residues at all.”
EXTENSIONS AND COMMENTARY: Most of the human trials took place in the fifteen to twenty milligram range. Several reports describe some muscular tremor, especially in the earliest part of the experience, but this never seemed to be a concern. The efforts to lock imagery to music were not too successful. All of these clinical studies were conducted on the trans-compound, but on the racemic mixture. This has been resolved into the two optical isomers, but they have not been compared in man. The cis-mixture is unknown.
This material is intimately related to tranylcypromine, a clinically proven antidepressant. This drug is a known monoamine oxidase inhibitor, and it is certainly possible that some of this pharmacological property might be found in DMCPA if it were to be looked for. The hints of physical toxicity at the higher doses assayed might suggest some such activity.
This compound, DMCPA, was modeled directly after the structure of
13 May 2016 · · Isomer Design
About PiHKAL · info
This version of Book II of PiHKAL is based on the Erowid online version, originally transcribed by Simson Garfinkle and converted into HTML by Lamont Granquist. I drew also on “Tyrone Slothrop’s” (Unfinished) Review of PIHKAL to enumerate the many analogues mentioned in PiHKAL but not described at length. Many, many others have since been added.
I have tried here to expunge any artifacts introduced by the earlier transcriptions and restore the typographic niceties found in the printed edition. I’ve also made minor changes to some chemical names in line with current nomenclature practice. Typically the change is little more than expanding a prefix or setting it in italics. The history page has further details.
“At the present time, restrictive laws are in force in the United States and it is very difficult for researchers to abide by the regulations which govern efforts to obtain legal approval to do work with these compounds in human beings.“No one who is lacking legal authorization should attempt the synthesis of any of the compounds described in these files, with the intent to give them to man. To do so is to risk legal action which might lead to the tragic ruination of a life. It should also be noted that any person anywhere who experiments on himself, or on another human being, with any of the drugs described herein, without being familiar with that drug’s action and aware of the physical and/or mental disturbance or harm it might cause, is acting irresponsibly and immorally, whether or not he is doing so within the bounds of the law.”
The copyright for Book I of PiHKAL has been reserved in all forms and it may not be distributed. Book II of PiHKAL may be distributed for non-commercial reproduction provided that the introductory information, copyright notice, cautionary notice and ordering information remain attached.
PiHKAL is the extraordinary record of the authors’ years exploring the chemistry and transformational power of phenethylamines. This book belongs in the library of anyone seeking a rational, enlightened and candid perspective on psychedelic drugs.
Though Sasha and Ann have put Book II of PiHKAL in the public domain, available to anyone, I strongly encourage you to buy a copy. We owe them — and there’s still nothing quite like holding a real book in your hands.
PiHKAL (ISBN 0-9630096-0-5) is available for US$24.50 (plus $10 domestic first-class shipping) from Transform Press.Transform Press,
Berkeley, CA 94701
510 · 934 · 4930 (voice)
510 · 934 · 5999 (fax)